Emerging studies have shown that the BCAA metabolic enzymes BCAT1 and BCAT2 are aberrantly activated and functionally required for malignant tumors such as chronic myeloid leukemia (61), acute myeloid leukemia (62), and PDAC (63). Here, BCAT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.